Australia's CSL has said its one-monthly treatment for hereditary angioedema has shown it is safe and effective in a phase 3 trial, and will be filed for approval in its current financial year which ...

The alternative text for this image may have been generated using AI. We performed these experiments on six independent occasions (we analysed pooled colonies on four occasions), each time with ...